stapokibart   Click here for help

GtoPdb Ligand ID: 13785

Synonyms: CM-310 | CM310
Approved drug Immunopharmacology Ligand
stapokibart is an approved drug
Compound class: Antibody
Comment: Stapokibart (CM310) is a humanized monoclonal antibody that targets interleukin-4 receptor α-subunit (IL-4Rα) [1]. It was designed for anti-inflammatory potential.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Liu W, Zhao Y, He Y, Yan X, Yu J, Song Q, Zhang L, Dong B, Xu G, Wang C et al.. (2024)
Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation.
iScience, 27 (9): 110721. [PMID:39262798]
2. Shirley M. (2025)
Stapokibart: First Approval.
Drugs, [Epub ahead of print]. [PMID:40095376]